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Abstract
Murine models of systemic lupus erythematosus (SLE) have shown
apparently contradictory evidence in that either (a) tumor necrosis
factor (TNF) expression was low and TNF administration helpful or
(b) TNF was high and TNF blockade of therapeutic benefit, depen-
ding on the mouse model investigated. In fact, TNF apparently has
both effects, checking autoimmunity, at least to some degree, and
fostering inflammation. TNF blockade regularly, but transiently,
induces or increases autoantibodies to chromatin and to phospho-
lipids. At the same time, open-label data suggest that TNF block-
ade suppresses inflammatory manifestations of SLE, and long-term
benefit was seen in patients with lupus nephritis. A controlled
clinical trial is under way.
Tumor necrosis factor (TNF) exerts a variety of physiologic
and pathogenic effects [1-6]. For example, TNF plays a major
role in the organogenesis of the lymphoid system in early
development; it has pro-apoptotic and anti-apoptotic effects,
depending on the underlying contextual situation; it controls
the activation and responsiveness of many cells, including
cells of the immune system; and it is a master switch in the
initiation and perpetuation of inflammatory responses
(Figure 1). When the role of TNF and TNF inhibition in
systemic lupus erythematosus (SLE)–especially the latter two
effects–is examined, modulation of the immune (and auto-
immune) reactivity and pro-inflammatory effects have to be
considered. Therefore, these effects will constitute the focus
of the current review.
The role of tumor necrosis factor in
controlling autoimmunity
Autoreactivity is a common feature of healthy individuals, both
on the cellular and humoral levels [7,8]. However, this type of
autoimmunity is usually well controlled, is often only transient,
and does not lead to disease. In contrast, in autoimmune
diseases, autoimmunity has escaped its stringent control and
become pathogenic.
For SLE, there exist a variety of murine models. They differ in
parts of their phenotype and especially in the underlying
genetic factors, which lead to their disease. With respect to
TNF, it is of particular interest that this cytokine appears to
play an immunoregulatory role in lupus-prone animals
(Table 1). However, this role is not at all uniform, and TNF has
different consequences depending upon the strain and the
stage of the disease.
Tumor necrosis factor can ameliorate murine
lupus
In 1988, Jacob and McDevitt [9] reported that NZB/W mice
showed diminished production of TNF, a defect stemming
from the otherwise healthy NZW parent, and proved that
NZB/W disease was at least partly reversible by
administration of recombinant TNF early in life. Gordon and
colleagues [10], upon repeating and expanding these
studies, saw similar beneficial effects of high-dose TNF, even
after nephritis had developed, but there was no long-term
protection against the disease. Gordon and Wofsy [11] also
found that the recombinant TNF had effects on cellular, but
not humoral, (auto)immunity. More recently, Kontoyiannis and
Kollias [12], by analyzing TNF-deficient NZB mice, re-estab-
lished the finding that TNF deficiency is an important driver of
lupus-like autoimmunity in certain strains. Whereas TNF-
competent NZB mice display a subtle autoimmune phenotype
only, TNF-deficient NZB mice developed severe lupus.
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Tumor necrosis factor can deteriorate murine
lupus
In contrast to the findings in NZB/W mice, in which the auto-
immune consequences of low TNF levels were profound, TNF
was found to be highly overexpressed in both sera and renal
tissue of MRL/lpr/lpr lupus mice and the levels of TNF corre-
lated with the degree of inflammatory organ disease [13,14].
Moreover, even in NZB/W mice, there is an increase in renal
TNF expression in conjunction with renal inflammation [15].
In fact, anti-TNF therapy was beneficial in MRL/lpr lupus.
TNF-targeted approaches improved inflammation in joints
[16] and lungs [17]. Likewise, TNF blockade improved
arthritis, pneumonitis, and skin disease of moth-eaten mice
[18] and nephritis and leukopenia in the C3H.SW mouse
[19], two additional lupus models. Of particular interest,
administration of low-dose TNF later in the course of NZB/W
disease accelerated renal demise [15], revealing that even in
this model, in which TNF was thought to be protective, the
cytokine has a dual role–beneficial and detrimental.
Autoantibodies under tumor necrosis factor
blockade in more organ-selective
autoimmune disease
When therapies that inhibited TNF, such as infliximab,
etanercept, and adalimumab, were introduced in patients with
rheumatoid arthritis (RA), spondylarthropathies (SpAs), or
Crohn disease (CD), the emergence of anti-nuclear anti-
bodies (ANAs) and anti-dsDNA (double-stranded DNA) was
observed [20-31].
New-onset ANAs were found in at least one fourth, and up to
two thirds, of ANA-negative patients, and this possibly
depended somewhat on the disease (Table 2). Auto-
antibodies to dsDNA, which are much more specific for SLE,
still emerged in 9% to 54% of the patients under infliximab
therapy, depending on the test system. By means of the
Crithidia luciliae immunofluorescence test (CLIFT), Charles
and colleagues [20] found anti-dsDNA in 22 of 156 patients
with RA (14%) whereas by radioimmunoassay (RIA) only 8
patients (5%) had clearly positive antibodies (>25 U/mL).
It is important to note that the vast majority of these anti-
dsDNA antibodies were of immunoglobulin (Ig) M isotype
(Table 1) and most probably were non-pathogenic. In contrast
to these IgM autoantibodies, the occurrence of IgG anti-
dsDNA antibodies appeared to be a relatively rare event.
However, these autoantibodies may be closely associated
with instances of SLE-like disease [20,27]. In this regard, it is
interesting that, whereas IgM anti-dsDNA autoantibodies were
found less frequently under TNF blockade with etanercept
[28], this compound induces lupus to an apparently similar
extent as antibodies to TNF [32]. In addition, formation of anti-
phospholipid antibodies, again mostly of IgM isotype, can
occur during TNF-inhibiting therapy [24,33] and very rarely
may lead to life-threatening vascular complications [33,34].
Drug-induced lupus and lupus nephritis under
tumor necrosis factor blockade
The induction of lupus-like disease by TNF blockers appears
to be quite uncommon, with an incidence of 0.5% to 1%
[20,25,35], and independent of the type of TNF-blocking
drug [32,36]. Moreover, TNF-blocker-induced lupus is usually
benign, with most patients developing fatigue or fever,
musculoskeletal or skin symptoms, changes in blood counts,
or serositis, but only rarely major organ disease, and these
symptoms resolve after TNF blockade is stopped [32,36].
Nevertheless, seven cases of nephritis occurring under anti-
TNF therapy have been reported [37-39]. Four of these cases
occurred under etanercept, two on infliximab, and one under
adalimumab. Of these seven patients, five treated with
etanercept or adalimumab had bona fide lupus nephritis.
Histology showed World Health Organization (WHO) class
IV (diffuse proliferative) glomerulonephritis in two cases and
class III and class V (membranous) nephritis in one case
each. One patient did not undergo renal biopsy. Despite
Figure 1
Relevant effects of tumor necrosis factor (TNF). TNF acts on the
hypothalamus to induce fever and on hepatocytes to induce an acute-
phase response, mainly via interleukin (IL)-1 and IL-6, respectively (blue
lines). TNF also exerts a wide variety of immunoregulatory (left) and
pro-inflammatory actions: TNF is involved in the maturation of dendritic
cells (DC) and activates endothelial cells (EC) and immune cells (black
lines). Chronic TNF often is a survival signal (green lines) and plays a
role in maintaining survival niches for long-lived plasma cells
(PlasmaC). Some of these effects are indirect in part, involving
cytokines such as IL-6 for B cells (B) and IL-18 for cytotoxic T cells
(Tc). On the other hand, chronic TNF exposure leads to the
disassembly of T-cell receptors (TCR), thus inhibiting T-cell responses,
and induces the expression of anti-apoptotic proteins, inhibiting
programmed cell death (red lines). Effects on many other cells, such as
fibroblasts or osteoclasts, were left out because of the focus on
immune regulation but are of major importance elsewhere. Ab,
antibodies; Ag, antigen; C’, complement; CR, complement receptors;
FcR, Fc receptor; IC, immune complex; MF, macrophage; MHC, major
histocompatibility complex; Th, T helper cell.Page 3 of 8
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these impressive histological findings, none of the five
patients had to undergo cyclophosphamide therapy, only one
was treated with mycophenolate mofetil (MMF) [39], and the
rest remitted under steroids and TNF blocker withdrawal only.
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Table 1
Tumor necrosis factor (TNF) expression and effects of recombinant TNF administration or TNF blockade in murine models of
systemic lupus erythematosus 
Model [Reference] TNF expression Effects of recombinant TNF Effects of TNF blockade/deficiency
NZB [12]  Normal NA Severe lupus in TNF–/– animals
NZB/W [9,10] Low High dose: late onset (if given early),  NA
prolonged survival
[15] High in nephritis Low dose (late): increased renal inflammation
MRL/lpr [13,14] High  NA Improved arthritis, pneumonitis
Moth-eaten [18] High  NA Improved skin, arthritis, pneumonitis
C3H.SW [19] High NA Less severe nephritis, leukocytopenia
NA, not assessed.
Table 2
Autoantibodies and drug-induced lupus under infliximab 
New ANA New anti-dsDNA New ACLA
Diagnosis Number Positive Positivea IgM IgG IgM IgG DIL Reference
RA 156 37 (24%) 22 (14%) 22 1 ND ND 1 [20]
RA 62 19 (31%) 7 (11%) 7 0 ND ND 0 [22]
RA 24 4 (17%) 13 (54%) 9-11 3-4 5 0 0 [24]
RA 59 24 (41%) 21 (36%) 19 2 ND ND 0 [26]
RA 53 29 (55%) 5 (9%) 22b 34b 0 0 2 [27]
RA 59 24 (41%) 29 (49%) 28 1 0 0 0 [28]
RA 57 28 (49%) ND 3 ND ND 1 [31]
All RA 413 165 (40%) 77 (19%) 4 (1.0%)
AS 15 9 (60%) 4 (27%) 4 0-1 1 3 0 [24]
SpA 21 12 (57%) 4 (19%) ND ND ND ND 0 [21]
SpA 35 25 (71%) 6 (17%) 6 0 ND ND 0 [22]
SpA 33 8 (24%) 11 (33%) 11 0 ND ND 0 [29]
All SpA 94 54 (57%) 25 (27%) 0 (0%)
CD 35 6 (17%) 3 (9%) ND ND ND ND 0 [23]
CD 125 71 (57%) 14 (11%) ND ND ND ND 2 [25]
CD 500 ND ND ND ND ND ND 3 [35]
CD 63 21 (33%) 9 (14%) ND 9 2 0 1 [30]
All CD 723 6 (0.8%)
All together 1,230 10 (0.8%)
aRadioimmunoassay or most conservative value reported; bvalues difficult to reconcile with the number of patients with anti-dsDNA antibodies as
measured by radioimmunoassay. ACLA, anti-cardiolipin antibodies; ANA, anti-nuclear antibodies; anti-dsDNA, antibodies to double-stranded DNA;
AS, ankylosing spondylitis; CD, Crohn disease; DIL, drug-induced lupus; Ig, immunoglobulin; ND, not determined/reported; RA, rheumatoid
arthritis; SpA, spondylarthropathies.Rationale for using tumor necrosis factor
inhibition to treat systemic lupus
erythematosus
Most clinical manifestations of SLE are the consequence of
inflammatory changes subsequent to immune complex
formation with Fc receptor and complement activation. In the
sera of SLE, in contrast to many other diseases, such as RA,
in which the pathogenic role of TNF is established despite
the difficulty to readily detect increases in serum levels, TNF
reaches levels of more than 100 pg/mL; moreover, TNF con-
centrations are significantly associated with clinical disease
activity [40-44]. Despite the very high serum levels of soluble
TNF receptors, which likewise correlate with disease activity
[42,43,45], the TNF circulating in lupus sera is bioactive [46].
TNF is evidently overexpressed not only in murine (see
above), but also in human lupus nephritis [47-50], and our
own data suggest that this increase is associated with (renal)
disease activity as estimated by histology [51]. In addition,
TNF expression was demonstrated in refractory subacute
cutaneous lupus erythematosus (SCLE) lesions [52].
Given the role of TNF as a strong mediator of inflammation,
the high levels of serum TNF in active SLE, and the over-
expression in renal tissue with active nephritis, we reasoned
that TNF blockade could be an efficient way to block inflam-
mation in afflicted organs, such as the kidney, the joints, or
the skin. However, in view of the autoimmunogenic potential
of inhibiting TNF, we tested TNF inhibition as a means to
interfere with the inflammatory response in SLE by adminis-
tering only an induction regime of four infusions of infliximab
within 10 weeks rather than by planning for long-term therapy.
Evidence for beneficial effects from
open-label trial and anecdotal reports
Before we can embark upon summarizing reports on individual
or small groups of cases, a word of caution is mandated.
Anecdotal reports or open-label trials cannot be regarded as
providing evidence of the results they claim to reflect. If they
use some objective measure, the hints they give may be slightly
stronger, but the ultimate information has to come from
randomized controlled clinical trials [53]. On the other hand,
open-label studies in RA [54], ankylosing spondylitis [55], and
CD were subsequently confirmed by controlled trials.
Moreover, the potential risks of the approach and the
heterogeneity of SLE with its life-threatening features justified
an open-label study as a first step. Finally, open-label
experience with TNF blockade in a homogeneous subset of the
disease (such as nephritis) with the use of objective laboratory
measures (such as levels of creatinine or proteinuria) would
allow for focussing a controlled trial once they reveal beneficial
effects. From this perspective, we embarked upon an open-
label trial several years ago and complemented the data
obtained with the anecdotal reports on individual cases that
were published in the literature. Although the evidence for
therapeutic efficacy of TNF blockade in SLE is still limited,
there are a minimum of 28 cases reported at least in abstract
form [56-61] and most of these are on the use of the chimeric
monoclonal antibody infliximab.
Tumor necrosis factor blockade and lupus
arthritis
Our own experience includes three patients with refractory
lupus polyarthritis, all of whom went into complete remission
within days after the first (approximately 5 mg/kg) infusion of
infliximab [56]. Similar to RA, this effect lasted for about
8 weeks after the last infusion of a series of four. Retreatment
was effective for the relapsing disease in a single patient for
whom this approach was tried but led to a further increase in
anti-dsDNA autoantibodies [62]. All of our patients were on
constant dosages of either azathioprine or methotrexate, as
were patients successfully treated in Brussels [59] and Kuwait
[60]. In contrast, Katz and colleagues [63] saw a frequent
decline in efficacy and severe infusion reactions in patients
who were treated with infliximab without such combination
with conventional disease-modifying anti-rheumatic drugs.
Tumor necrosis factor blockade and skin
involvement
The published experience on lupus skin disease includes two
patients with SCLE [64,65] who were successfully treated
with the combination of infliximab and azathioprine and with
etanercept, respectively. We have also seen overt and long-
lasting improvement of a butterfly rash following compas-
sionate care treatment with infliximab and azathioprine in a
patient with lupus nephritis.
Tumor necrosis factor blockade and lupus
nephritis
Twelve published patients with SLE treated with TNF
blockers had lupus nephritis. Among them were seven
patients with diffuse proliferative (WHO class IV) [56,58,
59,61] and at least four with membranous (WHO class V)
lupus nephritis [56,57,59]. Most patients were treated with
the combination of infliximab with azathioprine or MMF. One
pregnant patient received etanercept plus plasmapheresis
and intravenous immunoglobulin [58].
In all but three patients, TNF blocker therapy led to significant
long-term renal responses. This may easily reflect reporting
bias, but in a series of nine patients with lupus nephritis, in
which all SLE patients of the cooperating centers were
included if they had ever received infliximab, the data still
amounted to a success rate of two out of three [59].
It is important to stress an unexpected finding in the patients
with lupus nephritis who were successfully treated with only
four infusions of infliximab (and constant-dose azathioprine).
In lupus arthritis, the disease relapsed within 2 months after
the last infusion, whereas in lupus nephritis, the improvement
achieved lasted for several years in some of the patients
[59,62]. In fact, many patients further improved their
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renal function [56]. These findings, which suggest self-
perpetuation of the inflammatory events which is interfered
with by TNF blockade, have yet to be understood in detail.
It is also noteworthy that severe edema in one case of long-
standing nephritic syndrome resolved within 2 weeks despite
a much slower increase in serum albumin [56], suggesting
direct effects on vessel permeability [66]. Thus, TNF
blockers, and infliximab in particular, appear to rapidly reduce
inflammation, and probably also reduce vascular permeability,
in patients with inflammatory manifestations of SLE.
Autoantibodies under tumor necrosis factor
blockade in patients with systemic lupus
erythematosus
While dampening inflammation, TNF blockade with infliximab
induced an increase of autoantibodies in five out of seven
patients and increases in anti-cardiolipin-antibodies (ACLAs)
in four out of seven patients in our open-label trial [62,67].
Moreover, we observed increases in autoantibodies to
histones and/or chromatin in all seven patients, including
those without anti-dsDNA antibodies [62]. At least in part, the
increase in anti-histone and anti-chromatin antibodies
preceded the anti-dsDNA increase.
All of these antibodies were only transiently elevated and fell
back to baseline levels shortly after TNF blockade was
stopped. None of the patients experienced a lupus flare, and
serum complement levels remained stable [62,67].
Nevertheless, the induced antibodies to dsDNA were of high
affinity, as measured by RIA, and of IgG isotype, as deter-
mined by CLIFT. Although this could have been expected
given the preformed anti-dsDNA antibodies, the absence of
lupus flares requires clarification. Several explanations are
possible. First, at the time of inclusion into this study, some
patients may have had a non-pathogenic autoantibody profile,
which, even when activated and expanded, remained non-
pathogenic. Second, the increase in autoantibody levels was
only transient, whereas the longer-term presence of high
levels of pathogenic antibodies might be required to induce
complement activation and flares; such a notion is supported
by observations on the long-term presence of anti-dsDNA
antibodies before the onset of SLE symptoms [68]. Third, the
pronounced anti-inflammatory effects of infliximab may have
prevented damage despite the presence of potentially
pathogenic antibodies. Nevertheless, we have observed one
episode of deep vein thrombosis in temporal association with
a slight increase in ACLA in one patient with preformed IgG
ACLA [59], indicating that in individual patients the presence
of autoantibodies may be associated with clinical pathology.
Potential mechanisms of autoantibody
formation under tumor necrosis factor blockade
Several hypotheses have been proposed which may explain,
at least in part, how a (therapeutic) reduction in TNF activity
could lead to formation of autoantibodies against nuclear
components and phospholipids. One of these hypotheses
relates to the activation of interferon (IFN)-α. Because, under
normal circumstances, TNF downregulates IFN-α [69], it was
hypothesized that the reduction in TNF unleashed IFN-α, thus
fostering autoimmunity. However, in SLE, both IFN-α and TNF
are highly increased and the levels of both of these cytokines
are associated with disease activity [40-42,44]. This finding
not only challenges the hypothesis, but even suggests that
the reciprocal negative regulation of the two cytokines is not
functional in active SLE. Rather, the combined increase of
both TNF and IFN-α might contribute to the pathogenesis of
systemic autoimmunity.
Another hypothesis relates to prolonged B-cell survival upon
TNF inhibition. In a murine graft-versus-host disease system,
TNF blockade led to diminished production of IFN-γ,
diminished IFN-γ-induced CD95 (Fas) upregulation, and
diminished cytolytic activity, but to a significant increase in
anti-dsDNA antibodies [70]. This led the authors to hypothe-
size that TNF blockade hampers the elimination of auto-
immune B lymphocytes by cytotoxic T cells [70]. Because IL-
18, formerly called IFN-γ-inducing factor, is reduced by TNF
blockade in RA as well as in SLE [51,71], this mechanism
may play a role.
Chronic TNF exposure also directly impairs T-cell activation
by downmodulating T-cell receptor (TCR) components,
impairing TCR signalling, and attenuating antigen-driven
events [72,73]. Thus, inhibition of TNF may facilitate T-cell
activation. Finally, TNF blockade after chronic TNF exposure
may also lead to increased apoptosis [62]. The resulting
increase in apoptotic material could explain why the emerging
antibodies appear to exclusively target nuclear antigens and
phospholipids, both of which are expressed on apoptotic
bodies [74,75]. Thus, the combination of an increase in
accessible antigen, normalization in TCR function, and better
B-cell activation may help to explain the pathways to
increased lupus autoantibodies under TNF blockade.
Safety issues of tumor necrosis factor blocker
therapy for systemic lupus erythematosus
In our limited experience, treatment with only four infusions of
infliximab in combination with azathioprine or methotrexate
appeared to be fairly safe with regard to lupus flares [56]
despite the increase of autoantibodies [62]. However,
although it may hold true that the strong anti-inflammatory
effects of infliximab protect against the transient increase in
autoantibodies, occasional flares might well occur when more
patients are treated. Looking at potential consequences of a
likewise transient increase in ACLA, we have actually seen
one (single) episode of deep vein thrombosis [59], alerting to
such a possibility.
On the other hand, we did observe bacterial infections. Even
under short-term therapy (four infusions), we have seen a
Available online http://arthritis-research.com/content/10/1/202
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and an occasional episode of enteritis caused by Salmonella
enteritidis [59]. Longer-term therapy may in fact expose
patients to higher risks in this respect [59].
Infusion reactions were not seen when infliximab was
combined with azathioprine (or methotrexate). Only a single
episode occurred in a patient retreated 1.5 years after
cessation of infliximab [59]. This is likely due to the
combination given that others have regularly observed severe
infusion reactions in lupus arthritis patients for whom
infliximab was used in monotherapy [63].
Controlled trial of infliximab and azathioprine
in membranous lupus nephritis
These data indicate that short-term TNF blockade in
combination with azathioprine may be a step forward in the
therapy of patients with lupus nephritis. However, substantial
evidence can be derived only from a controlled clinical trial.
We recently embarked on a double-blind placebo-controlled
study called ‘TNF blockade with Remicade in Active Lupus
nephritis class V’, or TRIAL V. This study includes patients
with membranous lupus nephritis (WHO class V) in whom
corticosteroids and angiotensin-converting enzyme inhibitors
have failed to reduce proteinuria below 3 g/day. Patients are
randomly assigned either to the combination of azathioprine
plus four infusions (5 mg/kg) of infliximab or to azathioprine
monotherapy plus four placebo infusions (Figure 2). The
primary endpoint is time to reduction in proteinuria below
1.5 g/day.
Conclusion
Although our understanding of TNF in SLE has increased
considerably over the past few years, novel findings are well
in line with what had to be predicted from previous mouse
studies. On the one hand, TNF apparently has anti-
autoimmune effects and TNF blockade may lead to the
occurrence of autoantibodies. Whereas drug-induced lupus-
like disease is an uncommon, but established, adverse effect
of TNF blockade in patients with RA, SpA, or CD, these
autoantibodies hitherto have not induced lupus flares. On the
other hand, TNF appears to play a major pro-inflammatory
role in SLE also. The available open-label experience on
infliximab therapy in SLE suggests that, in combination with
azathioprine, infliximab may turn out to be an interesting
therapeutic option in selected patients with SLE and in
particular in those with nephritis. It will depend on controlled
clinical trials to decide this point. At least one such trial is
under way.
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